📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines (2021)

First Author: Monin-Aldama L

Attributed to: Evaluation of the CD4+ T cell tumour microenvironment of low grade B cell lymphoproliferative disorders funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.03.17.21253131

Publication URI: http://dx.doi.org/10.1101/2021.03.17.21253131

Type: Preprint